Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Rhythmic Light Therapy for Alzheimer's Disease Patients

NCT: NCT05015478 · COMPLETED

NCT IDNCT05015478
StatusCOMPLETED
Start Date2022-01-10
Completion2023-09-12
SponsorIcahn School of Medicine at Mount Sinai (OTHER)
First posted
Last updated

Brief Summary

The investigator will investigate how light delivering 40 hertz (Hz) affects subjective sleep and cognition in a controlled laboratory study. A lab study will allow the collection of electroencephalogram (EEG) data, perform cognitive tests, and observe the response in those with mild cognitive impairment (MCI) compared to a healthy control group (HC). Participants will attend two study sessions over the course of two weeks. During both sessions, all participants will experience 10 minutes of a low-level light, followed by a data collection period which involves a sleepiness rating, an electroencephalogram (EEG) recording, and a computerized memory test. Participants will then experience either a RL or a placebo RL condition for one hour, after which there will be a second data collection.

Frequently Asked Questions

What is Rhythmic Light Therapy for Alzheimer's Disease Patients?

Rhythmic Light Therapy for Alzheimer's Disease Patients is a clinical trial registered under NCT05015478. Current status: COMPLETED.

What is the status of NCT05015478?

The current status of NCT05015478 (Rhythmic Light Therapy for Alzheimer's Disease Patients) is: COMPLETED.

When did Rhythmic Light Therapy for Alzheimer's Disease Patients start?

Rhythmic Light Therapy for Alzheimer's Disease Patients started on 2022-01-10.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.